Hemophilia Market

Part
01
of three
Part
01

Market Growth Drivers for the Hemophilia Market in Africa

While there is no pre-existing information to fully answer your question, we've used the available data to pull together key findings and have identified six market growth drivers for the hemophilia market in Africa. These include the growth of disease conditions, continued and increasing use of the recombinant products, advancement in novel coagulating factors, increased investment in R&D for hemophilia products, and gene therapy advancements. Additional drivers and trends analysis in prophylactic treatment, growing demand for FVIII, and increasing diagnosis rate were not publicly available.

Below you'll find an outline of our research methodology to better understand why the information you've requested is publicly unavailable, as well as a deep dive into our findings.

Methodology

An extensive search of the public domain revealed very few news articles or government reports on the market growth drivers for the hemophilia market in Africa. We researched industry reports, health organizations reports like the World Health Organization, press releases on the hemophilia market in Africa, and health media and were unable to locate any publicly available information.

It's important to note that select publications, like Market Research Report, has global hemophilia drivers and trends available for purchase, and Infinium Research has Africa market growth drivers and trends analysis behind a paywall. Unfortunately, the data within these reports was not available in the public domain.

HELPFUL FINDINGS

The market growth drivers in Africa for hemophilia are listed in the Market Data Forecast. Each of these six factors is listed below. The market growth in 2016 had a CAGR of 1.77% and it is expected to reach $565.8 million by 2020.

1. Growing prevalence of the disease conditions- Awareness of the disease is also at a minimum of 1 in 5000 males who are born with the disease each year. More than 80% of those with hemophilia are considered to be severe. The World Health Organization has an Africa Summit of Hemophilia in November 2017 to discuss the disease and promoting awareness.

2. Increasing usage of recombinant product-As new EHL products are introduced globally and get into the drug approval process in Africa, more children will be able to get FVIII infusions and prophylactic therapy to help with the disease.

3. Advancements in the novel coagulating factors- As North America drives inception of new developments in coagulating factors and recombinants, the global market of coagulating factors is expected to be near 46.9% by the end of 2024.

4. Rising investments in Research and developments for hemophilia products- There has been a lack of available medicine and a high cost to treat hemophilia that have been holding the market back. North America is the driving force behind this and as they invest, develop, and control the market it will also trickle into Africa as products come up for approval.

5. Advancements in gene therapy- This is considered to have tremendous growth potential with advancements in therapy. In December 2017, Science Daily released an article on a gene therapy trial to help cure hemophilia. It included patients from the U.S., Europe, Africa, and South America.

6. Approaching approval of drugs for the treatment of hemophilia- Registering drugs in Africa is a lengthy process, several drugs that are already in the regulatory tray are slated to be approved over the next 12-18 months.

CONCLUSION

Despite the limited capabilities of internet archiving of market growth drivers in the areas of prophylactic treatment, growing demand for FVIII, and increasing diagnosis rate, we were able to find six growth drivers including the growth of disease conditions, continued and increasing use of the recombinant products, advancement in novel coagulating factors, increased investing in R&D for hemophilia products, and gene therapy advancements. Additional growth driver information on hemophilia in Africa was not publicly available as information was only available for purchase and not publicly available. There are market research reports available for purchase for the global market and the African market.
Part
02
of three
Part
02

Market Growth Drivers for the Hemophilia Market in Asia.

Hemophilia market overview - Asia

There are many market growth drivers for the Hemophilia market in Asia ranging from launch of newer innovative therapies, ease of access to medical facilities, growing awareness, increased focus on treating bleeding disorders, rising per capita income, availability of drugs, improving healthcare infrastructure, rising demand for prophylactic treatment, and so on.

Presently, based on the most recent report by the Pharmaceuticals Market Reports, The Asia-Pacific hemophilia A market is likely to reach $1,499,200,000 in 2023 growing from $838,900,000 in 2016 at a CAGR of 8.6%. Another report by GBI research forecasts that both the hemophilia A and B markets in Asia-Pacific will be valued at $699,100,000 and $112,900,000 in 2022 from $444,900,000 and $76,300,000 in 2015, at a CAGR of 6.7% and 5.8%. On the other hand, Strategic alliances are also on the rise in hemophilia A and B with deals ranging $10,000,000 to over $280,000,000.

MAJOR Factors driving Hemophilia Market in Asia

GBI research noted that the most significant driver of growth in the APAC haemophilia A and B markets would be the shift from short-acting to expensive long-acting replacement therapies such as Novo Nordisk’s N9-GP and CSL-Behring’s CSL-689. According to the report, these new products will launch sometime during the forecast period, and it is believed that they will capture a significant market share because they only require fewer injections and present convenient routes of administration.

Another major factor is the growing "treatment-receiving pool" facilitated by the ease of access to healthcare facilities in China and India, advancement in diagnostic technology, and free testing services for new and old patients in China.

Grandview research reported that presently, the market has several drugs for treating Hemophilia A, thereby undermining its growth over the forecast period. According to the report, type patients across North America, United Kingdom, Germany, Japan, India, China, and South Africa use Advate and Recombinate manufactured by Baxalta for prophylactic treatment. Besides, the pipeline shows a positive sign, shifting from factor replacement therapies to non-factor therapies and short-acting recombinant factor VIII or factor IX to long-acting recombinant factor VIII. However, in China and India, the high-expected prices for new long-acting recombinant therapies might facilitate their low penetration, therefore, becoming the main market restraint.

Other Factors
A report by Transparency Market Research noted that Asia-Pacific region has many lucrative opportunities to offer the hemophilia market, facilitated mainly by the increasingly demand for unmet medical needs. Other critical factors stimulating the growth include the growing per capita income, increasing awareness of the disorder, improving healthcare services, the emerging economies of Asia-Pacific, and the increasing focus on treating bleeding disorders. The research noted that these factors will give the overall hemophilia market an exceptional boost in the few years to come.

Across North America, Europe and Japan, prophylactic therapies are widely used following the World Federation of Hemophilia and WHO recommendation that prophylaxis therapy is the optimal therapy for hemophilia. This has stimulated the demand for prophylactic therapies in Asia-Pacific, and the availability of recombinant factor promises immense growth opportunities in the hemophilia market.


CONCLUSION
In conclusion, the shift from short-acting replacement therapies to costly long-acting replacement therapies, the growing treatment-receiving pool facilitated by advanced diagnostic technologies and ease of access to medical facilities, rising demand for unmet medical needs, increasing awareness of hemophilia, growing per capita income, and the impact of the emerging economies of scale are the key factors driving the hemophilia market in Asia.
Part
03
of three
Part
03

Market Growth Drivers for the Hemophilia Market in South America

There are four main drivers in the market growth of the Hemophilia market in South America. The drivers of the market include patient awareness, increased diagnosis, new treatment options, and increased investments in research and development. Below is a more in-depth analysis of our findings.

Methodology

To find the most recent and relevant information on the projected growth of the Hemophilia market in South America, we focused on finding industry reports from well-known market research companies such as Markets and Markets, Transparency Market Research, IBIS World, and similar market research companies. Several reports were located through PR Newswire, MarketData Forecast and Transparency Market Research, unfortunately, these reports focused on Latin America which included both Central and South America. Every attempt was made to find separate sources that focused on South America alone, however, none of the reports separated Central America from South America. During our search, we found that Latin America and South America are commonly used interchangeably, resulting in confusion. Due to this confusion, it is likely that reports focus on Latin America rather than South America to account for the confusion. Based on the findings of the research process, this analysis was drafted with confidence that the information provided is strongly relevant to the South American region.

FINDINGS

A report by MarketData Forecast focuses on the treatment market for Hemophilia A and B. According to this report, the main growth drivers for the Hemophilia market in South America include increased cases of malnutrition and increased instances of iron deficiency. Additionally, both MarketData Forecast and Transparency Market Research identify a growth in the prevalence and diagnosis of the disease. The increased diagnosis of Hemophilia can be attributed to the use of better diagnostic techniques. Awareness of the disease is also working as a driver in the growth of the Hemophilia market in South America. Based on reports released by PR Newswire, citizens in the region are also making themselves more aware of the disease and various treatments.
Investments in research, as well as advancements in treatments, are also driving the growth of the Hemophilia market. Due to the rise in Hemophilia cases, medical and pharmaceutical facilities have increased research on the disease. In some regions, the government is also increasing the funding for Hemophilia research. The increased attention to the disorder has led to new treatment options. Some of the treatments driving the overall market include recombinant products and prophylactic regimens. Notably, patients also prefer these new treatment options due to its low risk of blood-related infections. In return, patient preference for new treatments will continue to drive the market.

Conclusion

In summary, the main market growth drivers for the Hemophilia Market in South America revolve around awareness, diagnosis, treatment options, and research. Based on several reports, it was found that as diagnostic techniques become more improved, the cases of Hemophilia rise, which directly drives market growth. Secondly, patients are also becoming more aware of the disease and actively seeking information on rising treatment options. The increased diagnosis and awareness of the disorder have resulted in increased investments in research and development, driving the growth of the Hemophilia market in South America. Lastly, introductions of new and low-risk treatments are noted to drive the growth of the Hemophilia market in South America throughout the following years.

Sources
Sources